St. Clair Advisors LLC Invests $482,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

St. Clair Advisors LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 5,219 shares of the biopharmaceutical company’s stock, valued at approximately $482,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of GILD. HHM Wealth Advisors LLC lifted its position in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $28,000. Crews Bank & Trust purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $31,000. Stephens Consulting LLC lifted its position in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 2.2%

Shares of NASDAQ GILD opened at $102.50 on Monday. The company’s 50-day simple moving average is $105.75 and its 200-day simple moving average is $99.84. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The firm has a market cap of $127.50 billion, a price-to-earnings ratio of 277.03, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter last year, the business earned ($1.32) earnings per share. The company’s revenue for the quarter was down .3% compared to the same quarter last year. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 3.08%. Gilead Sciences’s payout ratio is presently 66.53%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $99.82, for a total transaction of $249,550.00. Following the transaction, the chief financial officer now directly owns 165,674 shares in the company, valued at approximately $16,537,578.68. The trade was a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 25,429 shares of company stock worth $2,894,445. 0.27% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on GILD shares. BMO Capital Markets increased their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Thursday, February 13th. Oppenheimer decreased their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, April 25th. Royal Bank of Canada raised their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald began coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price target for the company. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.